MX2022007875A - Nuevos marcadores proteicos de da?o renal. - Google Patents

Nuevos marcadores proteicos de da?o renal.

Info

Publication number
MX2022007875A
MX2022007875A MX2022007875A MX2022007875A MX2022007875A MX 2022007875 A MX2022007875 A MX 2022007875A MX 2022007875 A MX2022007875 A MX 2022007875A MX 2022007875 A MX2022007875 A MX 2022007875A MX 2022007875 A MX2022007875 A MX 2022007875A
Authority
MX
Mexico
Prior art keywords
methods
protein markers
renal damage
new protein
relates
Prior art date
Application number
MX2022007875A
Other languages
English (en)
Inventor
Serres Francisco E Borràs
Valdemoros L Ricardo Lauzurica
Planella Laura Carreras
Original Assignee
Fundacio Inst Dinvestigacio En Ciencies De La Salut Germans Trias I Pujol Igtp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Inst Dinvestigacio En Ciencies De La Salut Germans Trias I Pujol Igtp filed Critical Fundacio Inst Dinvestigacio En Ciencies De La Salut Germans Trias I Pujol Igtp
Publication of MX2022007875A publication Critical patent/MX2022007875A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7052—Fibrosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a marcadores proteicos de orina de daño renal o fenotipo patológico y métodos que usan los mismos. Se relaciona además con marcadores proteicos en la orina para determinar el grado de fibrosis en un riñón y métodos para usar los mismos. En particular, se refiere a métodos que usan tales biomarcadores en la vigilancia del paciente que padece de nefropatía crónica o después de un trasplante renal. Se refiere además a segundos usos médicos asociados, métodos de tratamiento, kits y uso de los mismos en los métodos de la invención.
MX2022007875A 2019-12-23 2020-12-18 Nuevos marcadores proteicos de da?o renal. MX2022007875A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19383190 2019-12-23
PCT/EP2020/087290 WO2021130138A1 (en) 2019-12-23 2020-12-18 New protein markers of renal damage

Publications (1)

Publication Number Publication Date
MX2022007875A true MX2022007875A (es) 2022-09-23

Family

ID=69172577

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007875A MX2022007875A (es) 2019-12-23 2020-12-18 Nuevos marcadores proteicos de da?o renal.

Country Status (5)

Country Link
US (1) US20230059874A1 (es)
EP (1) EP4081803A1 (es)
CA (1) CA3165653A1 (es)
MX (1) MX2022007875A (es)
WO (1) WO2021130138A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024041257A1 (zh) * 2022-08-23 2024-02-29 南京羿检医学科技有限公司 一种通过检测尿液迁移体来判断慢性肾病的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4913587B2 (ja) 2006-12-28 2012-04-11 雪印メグミルク株式会社 ペプチドおよびタンパク質定量法
WO2008146100A1 (en) 2007-06-01 2008-12-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for absolute quantification of polypeptides
ES2567276T3 (es) 2011-05-12 2016-04-21 Genentech, Inc. Método de LC-MS/MS de monitoreo de múltiples reacciones para detectar anticuerpos terapéuticos en muestras de animales usando péptidos de cambio de marco
WO2013078253A1 (en) 2011-11-22 2013-05-30 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2013158777A1 (en) 2012-04-17 2013-10-24 Icahn School Of Medicine At Mount Sinai Method for predicting risk of exposure to interstitial fibrosis and tubular atrophy with clusterin
KR102039816B1 (ko) 2018-02-06 2019-11-01 울산대학교 산학협력단 신장이식 후 이식 장기의 섬유증 진단 또는 예측용 바이오마커

Also Published As

Publication number Publication date
EP4081803A1 (en) 2022-11-02
US20230059874A1 (en) 2023-02-23
WO2021130138A1 (en) 2021-07-01
CA3165653A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
CR20210189A (es) Inhibidores de la proteina tirosina fosfatasa
PH12020551683A1 (en) Biomarkers for graft-versus-host disease
EP3761034A3 (en) Urine biomarkers for prediction of recovery after acute kidney injury: proteomics
MX2019005415A (es) Anticuerpos de il-6 y uso de los mismos.
WO2007146229A3 (en) Markers associated with arteriovascular events and methods of use thereof
NO20082311L (no) Terapeutisk middel for hjertesykdom
WO2007044860A3 (en) Diabetes-associated markers and methods of use thereof
DE602006019262D1 (de) QUANTITATIVE ASSAYS FÜR PDGFR-beta- IN KÖRPERFLÜSSIGKEITEN
JP2016519763A5 (es)
NO20092741L (no) DR6-antagonister og anvendelse derav ved behandling av neurologiske forstyrrelser
WO2007032876A3 (en) Biomarkers associated with age-related macular degeneration
WO2008137838A3 (en) Interferon alpha-induced pharmacodynamic markers
WO2006001931A3 (en) Prouroguanylin as therapeutic and diagnostic agents
WO2012054321A3 (en) Assays, methods and kits for predicting renal disease and personalized treatment strategies
WO2017027391A3 (en) Genetic abnormalities in plasma cell dyscrasias
WO2006027192A3 (en) Biomarkers for acute graft rejection
MX2022007875A (es) Nuevos marcadores proteicos de da?o renal.
DE60137264D1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
ATE336506T1 (de) Verwendung löslicher cytokeratin-1-fragmente in diagnostik
Stefaniak et al. Macrophage migration inhibitory factor as a potential predictor for requirement of renal replacement therapy after orthotopic liver transplantation
WO2020023789A3 (en) Small rna predictors for alzheimer's disease
MX2018011679A (es) Biomarcadores de proteopatias y usos de los mismos.
ATE486286T1 (de) Prognoseverfahren für kongestives herzversagen
WO2005065328A3 (en) Macrophage migration inhibitory factor (mif) as marker for urological inflammatory disease
WO2008024495A3 (en) Biomarkers associated with age-related macular degeneration